Hot Features
Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.
TUSCANY study is open to enroll patients to receive TUS+VEN+AZA triplet at select US sitesFavorable safety and broad clinical activity make tuspetinib an ideal agent to combine with venetoclax and...
SAN DIEGO and TORONTO, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing...
SAN DIEGO and TORONTO, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing...
SAN DIEGO and TORONTO, Aug. 30, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing...
SAN DIEGO and TORONTO, Aug. 15, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing...
TUS+VEN+HMA Triplet Protocol in Frontline Therapy for Newly Diagnosed AML was Reviewed by the FDA and Allowed to Proceed Abstract Supporting Exploration of the TUS+VEN+AZA Triplet in Frontline...
SAN DIEGO and TORONTO, July 19, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing...
SAN DIEGO and TORONTO, Sept. 05, 2017 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ:APTO) (TSX:APS), a clinical-stage company developing highly differentiated therapeutics that target...
SAN DIEGO and TORONTO, Aug. 08, 2017 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ:APTO) (TSX:APS), a clinical-stage company developing highly...
SAN DIEGO and TORONTO, Aug. 03, 2017 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ:APTO) (TSX:APS), a clinical-stage company developing highly differentiated therapeutics that target...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.165 | -30.5555555556 | 0.54 | 0.57 | 0.37 | 5883 | 0.52116055 | CS |
| 4 | -0.175 | -31.8181818182 | 0.55 | 0.58 | 0.37 | 4994 | 0.5336045 | CS |
| 12 | -0.155 | -29.2452830189 | 0.53 | 0.63 | 0.37 | 6074 | 0.52228194 | CS |
| 26 | -1.215 | -76.4150943396 | 1.59 | 1.69 | 0.37 | 7139 | 0.80280364 | CS |
| 52 | -3.705 | -90.8088235294 | 4.08 | 4.08 | 0.37 | 7322 | 1.59395095 | CS |
| 156 | -48.225 | -99.2283950617 | 48.6 | 49.2 | 0.37 | 17833 | 17.58413996 | CS |
| 260 | -49.275 | -99.2447129909 | 49.65 | 189.3 | 0.37 | 35362 | 79.91972323 | CS |
| Keine Diskussionen Gefunden. |
| Neuen Thread Erstellen |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
